Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Associations between YKL-40 and markers of disease severity and death in patients with necrotizing soft-tissue infection

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Monocyte count and soluble markers of monocyte activation in people living with HIV and uninfected controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The prevalence of diabetes among tuberculosis patients in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Development of a core outcome set for general intensive care unit patients - a protocol

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Potential Advances of Adjunctive Hyperbaric Oxygen Therapy in Infective Endocarditis

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Background: Necrotizing soft-tissue infection (NSTI) is a severe and fast-progressing bacterial infection. Prognostic biomarkers may provide valuable information in treatment guidance and decision-making, but none have provided sufficient robustness to have a clinical impact. YKL-40 may reflect the ongoing pathological inflammatory processes more accurately than traditional biomarkers as it is secreted by the activated immune cells, but its prognostic yields in NSTI remains unknown. For this purpose, we investigated the association between plasma YKL-40 and 30-day mortality in patients with NSTI, and assessed its value as a marker of disease severity. Methods: We determined plasma YKL-40 levels in patients with NSTI (n = 161) and age-sex matched controls (n = 65) upon admission and at day 1, 2 and 3. Results: Baseline plasma YKL-40 was 1191 ng/mL in patients with NSTI compared with 40 ng/mL in controls (p < 0.001). YKL-40 was found to be significantly higher in patients with septic shock (1942 vs. 720 ng/mL, p < 0.001), and in patients receiving renal-replacement therapy (2382 vs. 1041 ng/mL, p < 0.001). YKL-40 correlated with Simplified Acute Physiology Score II (Rho 0.33, p < 0.001). Baseline YKL-40 above 1840 ng/mL was associated with increased risk of 30-day mortality in age-sex-comorbidity adjusted analysis (OR 3.77, 95% CI; 1.59–9.24, p = 0.003), but after further adjustment for Simplified Acute Physiology Score II no association was found between YKL-40 and early mortality. Conclusion: High plasma YKL-40 to be associated with disease severity, renal-replacement therapy and risk of death in patients with NSTI. However, YKL-40 is not an independent predictor of 30-day mortality.

Original languageEnglish
Article number1046
JournalBMC Infectious Diseases
Volume21
Issue number1
Pages (from-to)1046
ISSN1471-2334
DOIs
Publication statusPublished - 9 Oct 2021

Bibliographical note

© 2021. The Author(s).

    Research areas

  • Biomarkers, Chitinase-3-Like Protein 1, Humans, Severity of Illness Index, Shock, Septic, Soft Tissue Infections, Clinical endpoint, Fournier’s gangrene, Necrotizing fasciitis, Sepsis, Chitinase-3-like-1 protein, Survival

ID: 69208868